Get the Stockscreener App
0.98
1.01%
-0.01
After Hours:
.98
Enlivex Therapeutics Ltd stock is traded at $0.98, with a volume of 60,673.
It is down -1.01% in the last 24 hours and down -16.95% over the past month.
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.
See More
Previous Close:
$0.99
Open:
$1.01
24h Volume:
60,673
Relative Volume:
0.32
Market Cap:
$21.55M
Revenue:
-
Net Income/Loss:
$-22.29M
P/E Ratio:
-0.8305
EPS:
-1.18
Net Cash Flow:
$-17.12M
1W Performance:
-6.67%
1M Performance:
-16.95%
6M Performance:
-20.33%
1Y Performance:
-67.76%
1-Day Range:
$0.9701
$1.0132
1-Week Range:
$0.9701
$1.09
52-Week Range:
$0.8101
$4.59
Enlivex Therapeutics Ltd Stock (ENLV) Company Profile
Name
Enlivex Therapeutics Ltd
Sector
Industry
Phone
-
Address
-
Compare ENLV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ENLV
Enlivex Therapeutics Ltd
|
0.98 | 21.55M | 0 | -22.29M | -17.12M | -1.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
480.35 | 123.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
723.47 | 79.09B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
624.94 | 37.97B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.20 | 31.74B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
259.70 | 27.71B | 3.32B | -860.46M | -1.04B | -8.32 |
Enlivex Therapeutics Ltd Stock (ENLV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-02-21 | Reiterated | H.C. Wainwright | Buy |
Enlivex Therapeutics Ltd Stock (ENLV) Latest News
Enlivex Advances Immunotherapy with Japanese Patent for Osteoarthritis Treatment - PUNE.NEWS
Enlivex Therapeutics (NASDAQ:ENLV) Hails Positive Trial Results for Allocetra Treatment of Knee Osteoarthritis - Markets Insider
Enlivex Therapeutics Starts Phase II Allocetra Trail to Treat Knee Osteoarthritis - Markets Insider
Enlivex Wins Key Patent in Japan for Osteoarthritis Treatment - Markets Insider
Enlivex Therapeutics Completes Initial Dosing in Phase I Psoriatic Arthritis Trial - Markets Insider
Enlivex Therapeutics Denies False Report of Trading Suspension and Reaffirms Business Operations - Nasdaq
Enlivex Takes Legal Action Against Market Manipulation as Stock Trading Continues Uninterrupted - StockTitan
CollPlant Biotechnologies Provides a Corporate Update - Quantisnow
Tryptamine Therapeutics Appoints New Auditor Amid Global Expansion - TipRanks
RedChip Announces Webinar to Teach Investors How to Use RedChat, a Revolutionary AI Chatbot for Small-Cap Stock Analysis - Yahoo Finance
Enlivex Therapeutics’ (ENLV) “Buy” Rating Reiterated at D. Boral Capital - Defense World
Enlivex Therapeutics (NASDAQ:ENLV) Stock Price Up 1.9% – Time to Buy? - Defense World
Sepsis Market Forecasted to Surge in Coming Years, 2024-2034 - openPR
Enlivex Receives Regulatory Authorization From Israel’s Health Ministry For The Initiation Of Phase 1/2 Trial Evaluating Allocetra In Patients With Knee Osteoarthritis - ACCESS Newswire
Enlivex Therapeutics and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - ACCESS Newswire
Join Enlivex Therapeutics' Exclusive Live Investor Webinar and Q&A Session on December 3 - ACCESS Newswire
Head-To-Head Analysis: Bright Minds Biosciences (NASDAQ:DRUG) versus Enlivex Therapeutics (NASDAQ:ENLV) - Defense World
Enlivex CEO to Showcase Breakthrough Allocetra Cell Therapy on Bloomberg TV Special Feature - StockTitan
Hoth’s phase IIa derma data in cancer patients propels its stock - BioWorld Online
Enlivex Therapeutics (NASDAQ:ENLV) Stock Price Up 6% – Still a Buy? - Defense World
Enlivex gains Israeli regulatory approval to commence TMJ osteoarthritis trial - Yahoo Finance
Enlivex Receives Regulatory Authorization for the Initiation of A Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis - Marketscreener.com
Enlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis - The Manila Times
Enlivex Therapeutics Advances Allocetra Program with New Phase I Trial for TMJ Osteoarthritis Treatment - StockTitan
Enlivex Announces Positive Interim Efficacy Data from Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis - The Manila Times
Trump's crypto advocacy steers businesses away from traditional treasury assets - Yahoo Canada Finance
Enlivex's Allocetra Trial Shows 50% Pain Reduction in Knee Osteoarthritis Study - StockTitan
Enlivex Therapeutics Faces Financial Challenges Amid Losses - TipRanks
Enlivex to Showcase Promising Allocetra™ Cell Therapy Data in Exclusive Investor Webinar | ENLV Stock News - StockTitan
Enlivex Therapeutics to Invest in Bitcoin as Part of Cash Management Strategy - Binance
Enlivex Therapeutics : Adopts Bitcoin Treasury Reserve Strategy Form 6 K - Marketscreener.com
Enlivex Therapeutics : X Adopts Bitcoin Treasury Reserve Strateg - Marketscreener.com
Enlivex Adopts Bitcoin Treasury Reserve Strategy - GlobeNewswire
Enlivex Therapeutics to Buy Up to $1M in Bitcoin as Treasury Reserve Asset | ENLV Stock News - StockTitan
Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Sees Significant Growth in Short Interest - Defense World
Armistice Capital, LLC Expands Stake in Enlivex Therapeutics Ltd - GuruFocus.com
Enlivex Announces the Dosing of the First Patient in a - GlobeNewswire
Enlivex Launches Phase I Trial for Novel Psoriatic Arthritis Treatment Allocetra™ | ENLV Stock News - StockTitan
Enlivex stock hits 52-week low at $1.15 amid market challenges - Investing.com Canada
Enlivex Announces the Enrollment and Dosing of the First 10 - GlobeNewswire
Enlivex's Allocetra Advances: Phase II Trial Launches for Knee Osteoarthritis Treatment | ENLV Stock News - StockTitan
Enlivex Therapeutics (ENLV) Upgraded to Strong Buy: Here's What You Should Know - MSN
Enlivex Therapeutics Reschedules Annual Shareholders Meeting - TipRanks
Enlivex Receives Notice of Allowance for Japanese Patent - GlobeNewswire
Enlivex Receives Notice of Allowance for Japanese Patent Application Covering the Use of Allocetra™ in Patients with Osteoarthritis - StockTitan
New Strong Buy Stocks for October 23rd - MSN
Enlivex stock moves forward as Danish agency approves Phase 2 for knee OA By Investing.com - Investing.com South Africa
Enlivex stock moves forward as Danish agency approves Phase 2 for knee OA - Investing.com Australia
EF Hutton maintains price target on Enlivex after trial advancement By Investing.com - Investing.com Australia
Enlivex Therapeutics Ltd Stock (ENLV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.53%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):